guest ::
| Home > Publications database > Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. > print |
| Home > Publications database > Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. > print |
| 001 | 181850 | ||
| 005 | 20240229145659.0 | ||
| 024 | 7 | _ | |a 10.1136/bmj-2022-070346 |2 doi |
| 024 | 7 | _ | |a pmid:36130770 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9490551 |2 pmc |
| 024 | 7 | _ | |a 0959-535X |2 ISSN |
| 024 | 7 | _ | |a 0959-8138 |2 ISSN |
| 024 | 7 | _ | |a 0959-8146 |2 ISSN |
| 024 | 7 | _ | |a 0959-8154 |2 ISSN |
| 024 | 7 | _ | |a 1756-1833 |2 ISSN |
| 024 | 7 | _ | |a 1759-2151 |2 ISSN |
| 024 | 7 | _ | |a altmetric:136240364 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02265 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Bundred, James R |b 0 |
| 245 | _ | _ | |a Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. |
| 260 | _ | _ | |a London |c 2022 |b British Medical Association |
| 264 | _ | 1 | |3 online |2 Crossref |b BMJ |c 2022-09-21 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1673508719_15371 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a To determine if margin involvement is associated with distant recurrence and to determine the required margin to minimise both local recurrence and distant recurrence in early stage invasive breast cancer.Prospectively registered systematic review and meta-analysis of literature.Medline (PubMed), Embase, and Proquest online databases. Unpublished data were sought from study authors.Eligible studies reported on patients undergoing breast conserving surgery (for stages I-III breast cancer), allowed an estimation of outcomes in relation to margin status, and followed up patients for a minimum of 60 months. Patients with ductal carcinoma in situ only or treated with neoadjuvant chemotherapy or by mastectomy were excluded. Where applicable, margins were categorised as tumour on ink (involved), close margins (no tumour on ink but <2 mm), and negative margins (≥2 mm).68 studies from 1 January 1980 to 31 December 2021, comprising 112 140 patients with breast cancer, were included. Across all studies, 9.4% (95% confidence interval 6.8% to 12.8%) of patients had involved (tumour on ink) margins and 17.8% (13.0% to 23.9%) had tumour on ink or a close margin. The rate of distant recurrence was 25.4% (14.5% to 40.6%) in patients with tumour on ink, 8.4% (4.4% to 15.5%) in patients with tumour on ink or close, and 7.4% (3.9% to 13.6%) in patients with negative margins. Compared with negative margins, tumour on ink margins were associated with increased distant recurrence (hazard ratio 2.10, 95% confidence interval 1.65 to 2.69, P<0.001) and local recurrence (1.98, 1.66 to 2.36, P<0.001). Close margins were associated with increased distant recurrence (1.38, 1.13 to 1.69, P<0.001) and local recurrence (2.09, 1.39 to 3.13, P<0.001) compared with negative margins, after adjusting for receipt of adjuvant chemotherapy and radiotherapy. In five studies published since 2010, tumour on ink margins were associated with increased distant recurrence (2.41, 1.81 to 3.21, P<0.001) as were tumour on ink and close margins (1.44, 1.22 to 1.71, P<0.001) compared with negative margins.Involved or close pathological margins after breast conserving surgery for early stage, invasive breast cancer are associated with increased distant recurrence and local recurrence. Surgeons should aim to achieve a minimum clear margin of at least 1 mm. On the basis of current evidence, international guidelines should be revised.CRD42021232115. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 542 | _ | _ | |i 2022-09-21 |2 Crossref |u http://creativecommons.org/licenses/by-nc/4.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 2 | |a Breast: pathology |2 MeSH |
| 650 | _ | 2 | |a Breast Neoplasms |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Margins of Excision |2 MeSH |
| 650 | _ | 2 | |a Mastectomy |2 MeSH |
| 650 | _ | 2 | |a Mastectomy, Segmental |2 MeSH |
| 650 | _ | 2 | |a Neoplasm Recurrence, Local |2 MeSH |
| 700 | 1 | _ | |a Michael, Sarah |b 1 |
| 700 | 1 | _ | |a Stuart, Beth |b 2 |
| 700 | 1 | _ | |a Cutress, Ramsey I |b 3 |
| 700 | 1 | _ | |a Beckmann, Kerri |b 4 |
| 700 | 1 | _ | |a Holleczek, Bernd |0 P:(DE-He78)53e1a2846c69064e27790dbf349ccaec |b 5 |u dkfz |
| 700 | 1 | _ | |a Dahlstrom, Jane E |b 6 |
| 700 | 1 | _ | |a Gath, Jacqui |b 7 |
| 700 | 1 | _ | |a Dodwell, David |b 8 |
| 700 | 1 | _ | |a Bundred, Nigel J |0 0000-0001-6007-056X |b 9 |
| 773 | 1 | 8 | |a 10.1136/bmj-2022-070346 |b BMJ |d 2022-09-21 |p e070346 |3 journal-article |2 Crossref |t BMJ |y 2022 |x 1756-1833 |
| 773 | _ | _ | |a 10.1136/bmj-2022-070346 |g Vol. 378, p. e070346 - |0 PERI:(DE-600)1479799-9 |p e070346 |t The BMJ |v 378 |y 2022 |x 1756-1833 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:181850 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)53e1a2846c69064e27790dbf349ccaec |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2022-11-15 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-15 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-15 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BMJ-BRIT MED J : 2021 |d 2022-11-15 |
| 915 | _ | _ | |a IF >= 90 |0 StatID:(DE-HGF)9990 |2 StatID |b BMJ-BRIT MED J : 2021 |d 2022-11-15 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1245/s10434-014-3480-5 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |2 Crossref |u Kennedy I. Review of the response of Heart of England NHS Foundation Trust to concerns about Mr I Paterson’s Surgical Practice: lessons to be learned and recommendations. (2013). |
| 999 | C | 5 | |a 10.1016/S0140-6736(14)60488-8 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1200/JCO.2014.55.1572 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |2 Crossref |u National Institute for Clinical Excellence. NG101: Early and locally advanced breast cancer: diagnosis and management. (2018). |
| 999 | C | 5 | |a 10.1097/SLA.0000000000001930 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |2 Crossref |u Bundred J, Dodwell D, Cutress R, Michael S, Bundred N. The impact of positive or close margins following breast conserving surgery for early stage breast cancer: a systematic review and meta-analysis. 2021. PROSPERO: CRD42021232115. |
| 999 | C | 5 | |a 10.1136/bmj.b2700 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1111/j.1398-9995.2009.01973.x |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1002/sim.1203 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1002/9781119536604.ch6 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1136/bmj.g7594 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |2 Crossref |u Dias S Sutton AJ Welton NJ Ades AE . Heterogeneity: Subgroups. Meta-Regression, Bias And Bias-Adjustment, 2012. |
| 999 | C | 5 | |a 10.1200/JCO.2001.19.6.1688 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1309/8941VDAJMKY2GCLX |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1080/02841860802032769 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.breast.2013.02.018 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3109/0284186X.2016.1167955 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1007/s10549-016-3732-0 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.ijrobp.2018.03.005 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1186/s12885-019-5710-5 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.radonc.2006.11.009 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1002/jso.24224 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1053/clon.2002.0165 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.ejso.2007.04.008 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.ijrobp.2014.04.039 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1007/s10549-016-4031-5 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/S0960-9776(17)30396-X |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.ejso.2018.06.014 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1245/s10434-015-5067-1 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1002/bjs5.50121 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/S0360-3016(03)00740-5 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1308/003588410X12699663903476 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.ijrobp.2011.02.021 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1007/s10549-015-3579-9 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1245/s10434-013-3416-5 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.breast.2014.09.009 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1007/s00268-014-2651-7 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1245/s10434-016-5407-9 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/S0360-3016(98)00519-7 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.ejso.2008.11.001 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1093/annonc/mdz173 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.ejca.2016.05.010 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.21614/chirurgia.113.2.253 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |2 Crossref |u National Institute for Clinical Excellence. NICE Appraisal Guidance No. 30 – The use of taxanes for the treatment of breast cancer, September 2001. (2002). |
| 999 | C | 5 | |a 10.1245/s10434-015-4626-9 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |2 Crossref |u General Medical Council. GMC: decision making and consent. (2020) https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/decision-making-and-consent/how-to-use-this-guidance. |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|